Stephen A. Migueles, M.D.

Cellular Immune Response Unit

NIH Main Campus, Bethesda, MD

Stephen A. Migueles, M.D.

Head, Cellular Immune Response Unit,
HIV-Specific Immunity Section, Laboratory of Immunoregulation

Contact: For contact information, search the NIH Enterprise Directory.

Photo of Stephen A. Migueles, M.D.

Major Areas of Research

  • Cellular immune response to HIV, SARS-CoV-2 and other infections
  • Mechanisms of durable immunologic control of HIV in rare patients
  • Basic immunology of vaccine-induced responses
  • Studies in a cohort of People Living with HIV Infection in Liberia, West Africa

Program Description

The major focus of the Cellular Immune Response Unit/HIV-Specific Immunity Section is identification of the mechanisms of an effective cellular immune response to HIV and other viral infections. Investigations are performed by various techniques on samples from rare patients, termed long-term nonprogressors (LTNPs) or elite controllers, who have exhibited spontaneous control of HIV replication for decades. Detailed characterization of their virus-specific T-cell responses is a critical step toward the development of effective vaccines and immunotherapies and provides fundamental insights into the regulation of human immune responses in viral infection and other disease states.



M.D., 1993, University of Miami Leonard M. Miller School of Medicine, Miami, FL

In 1997, Dr. Migueles came to the National Institute of Allergy and Infectious Diseases as a Clinical Associate in the Laboratory of Immunoregulation and was commissioned as a Medical Officer in the U.S. Public Health Service (USPHS). He became a Staff Clinician in 2005, Senior Research Physician in 2017 and Head of the Cellular Immune Response Unit in 2019. Dr. Migueles was promoted to CAPT (0-6) in the USPHS in 2010. He maintains active certification in Internal Medicine and Infectious Diseases (current diplomate, American Board of Internal Medicine).

Selected Publications

Matsuda K, Migueles SA, Huang J, Bolkhovitinov L, Stuccio S, Griesman T, Pullano AA, Kang BH, Ishida E, Zimmerman M, Kashyap N, Martins KM, Stadlbauer D, Pederson J, Patamawenu A, Wright N, Shofner T, Evans S, Liang CJ, Candia J, Biancotto A, Fantoni G, Poole A, Smith J, Alexander J, Gurwith M, Krammer F, Connors M. A replication-competent adenovirus-vectored influenza vaccine induces durable systemic and mucosal immunity. J Clin Invest. 2021 Mar 1;131(5):e140794.

Migueles SA, Rogan DC, Gavil NV, Kelly EP, Toulmin SA, Wang LT, Lack J, Ward AJ, Pryal PF, Ludwig AK, Medina RG, Apple BJ, Toumanios CN, Poole AL, Rehm CA, Jones SE, Liang CJ, Connors M. Antigenic Restimulation of Virus-Specific Memory CD8+ T Cells Requires Days of Lytic Protein Accumulation for Maximal Cytotoxic Capacity. J Virol. 2020 Nov 9;94(23):e01595-20.

Migueles SA, Chairez C, Lin S, Gavil NV, Rosenthal DM, Pooran M, Natarajan V, Rupert A, Dewar R, Rehman T, Sherman BT, Adelsberger J, Leitman SF, Stroncek D, Morse CG, Connors M, Lane HC, Kovacs JA. Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. JCI Insight. 2019 Sep 19;4(18):e130664.

Mendoza D, Johnson SA, Peterson BA, Natarajan V, Salgado M, Dewar RL, Burbelo PD, Doria-Rose NA, Graf EH, Greenwald JH, Hodge JN, Thompson WL, Cogliano NA, Chairez CL, Rehm CA, Jones S, Hallahan CW, Kovacs JA, Sereti I, Sued O, Peel SA, O'Connell RJ, O'Doherty U, Chun TW, Connors M, Migueles SA. Comprehensive analysis of unique cases with extraordinary control over HIV replication. Blood. 2012 May 17;119(20):4645-55.

Migueles SA, Rood JE, Berkley AM, Guo T, Mendoza D, Patamawenu A, Hallahan CW, Cogliano NA, Frahm N, Duerr A, McElrath MJ, Connors M. Trivalent adenovirus type 5 HIV recombinant vaccine primes for modest cytotoxic capacity that is greatest in humans with protective HLA class I alleles. PLoS Pathog. 2011 Feb;7(2):e1002002.

Migueles SA, Osborne CM, Royce C, Compton AA, Joshi RP, Weeks KA, Rood JE, Berkley AM, Sacha JB, Cogliano-Shutta NA, Lloyd M, Roby G, Kwan R, McLaughlin M, Stallings S, Rehm C, O'Shea MA, Mican J, Packard BZ, Komoriya A, Palmer S, Wiegand AP, Maldarelli F, Coffin JM, Mellors JW, Hallahan CW, Follman DA, Connors M. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity. 2008 Dec 19;29(6):1009-21.

Content last reviewed on